Acyclovir-resistant, foscarnet-sensitive oral herpes simplex type 2 lesion in a patient with AIDS.

[1]  C. Crumpacker,et al.  Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. , 1989, The New England journal of medicine.

[2]  D. Shanson,et al.  ACYCLOVIR-RESISTANT HERPES IN AIDS TREATED WITH FOSCARNET , 1988, The Lancet.

[3]  S. Walmsley,et al.  Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (Foscarnet). , 1988, The Journal of infectious diseases.

[4]  F. Gudat,et al.  Disseminated herpes simplex type 2 and systemic Candida infection in a patient with previous asymptomatic human immunodeficiency virus infection. , 1988, The Journal of infectious diseases.

[5]  J. Craig,et al.  ACYCLOVIR-RESISTANT HERPES SIMPLEX VIRUS INFECTION DUE TO ALTERED DNA POLYMERASE , 1987, The Lancet.

[6]  R. Tenser,et al.  Acyclovir resistance in a patient with chronic mucocutaneous herpes simplex infection. , 1987, Journal of the American Academy of Dermatology.

[7]  S. Straus,et al.  Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity , 1987, Antimicrobial Agents and Chemotherapy.

[8]  R. Schinazi,et al.  Characterization of acyclovir-resistant and -sensitive herpes simplex viruses isolated from a patient with an acquired immune deficiency. , 1986, The Journal of antimicrobial chemotherapy.

[9]  L. Corey,et al.  Recurrent genital herpes and suppressive oral acyclovir therapy. Relation between clinical outcome and in-vitro drug sensitivity. , 1986, Annals of internal medicine.

[10]  L. Corey,et al.  Infections with herpes simplex viruses (1). , 1986, The New England journal of medicine.

[11]  M. Grossman,et al.  Chronic perianal herpes simplex in immunocompromised hosts. , 1986, The American journal of medicine.

[12]  O. Ringdén,et al.  Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. , 1986, The Journal of antimicrobial chemotherapy.

[13]  S. Redding,et al.  The incidence of oral herpes simplex virus infection in patients undergoing cancer chemotherapy. , 1986, Oral surgery, oral medicine, and oral pathology.

[14]  M. Greenberg,et al.  Chronic oral herpes simplex virus infection in immunocompromised patients. , 1985, Oral surgery, oral medicine, and oral pathology.

[15]  D. Alling,et al.  Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir. , 1984 .

[16]  J. Meyers,et al.  Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir. , 1983, The Journal of infectious diseases.

[17]  L. Corey,et al.  In vitro sensitivity to acyclovir in genital herpes simplex viruses from acyclovir-treated patients. , 1983, The Journal of infectious diseases.

[18]  C. Wilfert,et al.  Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child. , 1982, The Journal of infectious diseases.

[19]  D. Parris,et al.  Herpes simplex virus variants restraint to high concentrations of acyclovir exist in clinical isolates , 1982, Antimicrobial Agents and Chemotherapy.

[20]  O. Laskin,et al.  ISOLATION AND CHARACTERISATION OF RESISTANT HERPES SIMPLEX VIRUS AFTER ACYCLOVIR THERAPY , 1982, The Lancet.

[21]  C. Crumpacker,et al.  Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. , 1982, The New England journal of medicine.

[22]  C. Cunningham-Rundles,et al.  Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. , 1981, The New England journal of medicine.

[23]  N. Flournoy,et al.  Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. , 1980, The Journal of infectious diseases.

[24]  R. Whitley,et al.  Identification of patients with increased risk of infection with herpes simplex virus after renal transplantation. , 1979, The Journal of infectious diseases.

[25]  H. Schaeffer,et al.  Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[26]  O. Jonasson,et al.  Prospective study of prevalence, incidence, and source of herpesvirus infections in patients with renal allografts. , 1977, The Journal of infectious diseases.

[27]  P. Fayers,et al.  DRIED-MILK INFANT FEEDS , 1976, The Lancet.

[28]  G. Selzer.  CHELATING AGENTS IN WILSON'S DISEASE. , 1963, Lancet.

[29]  H. Kessler,et al.  Severe, progressive herpetic whitlow caused by an acyclovir-resistant virus in a patient with AIDS. , 1988, The Journal of infectious diseases.

[30]  D. King.  History, pharmacokinetics, and pharmacology of acyclovir. , 1988, Journal of the American Academy of Dermatology.

[31]  C. Crumpacker.  Significance of resistance of herpes simplex virus to acyclovir. , 1988, Journal of the American Academy of Dermatology.

[32]  L. Corey,et al.  Infections with herpes simplex viruses. (Second of two parts) , 1986 .

[33]  H. Prentice,et al.  Antiviral therapy in the immunocompromised patient. , 1985, British medical bulletin.

[34]  C. Mclaren,et al.  Virus resistance in clinical practice. , 1983, The Journal of antimicrobial chemotherapy.

[35]  G. Elion.  The biochemistry and mechanism of action of acyclovir. , 1983, The Journal of antimicrobial chemotherapy.

[36]  B. Öberg.  Antiviral effects of phosphonoformate (PFA, foscarnet sodium). , 1982 .